Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Antineoplastic Agents, Immunological"" wg kryterium: Temat


Tytuł:
GT-00AxIL15, a Novel Tumor-Targeted IL-15-Based Immunocytokine for the Treatment of TA-MUC1-Positive Solid Tumors: Preclinical In Vitro and In Vivo Pharmacodynamics and Biodistribution Studies.
Autorzy:
Gellert J; Glycotope GmbH, Robert-Roessle-Str.10, 13125 Berlin, Germany.
Jäkel A; Glycotope GmbH, Robert-Roessle-Str.10, 13125 Berlin, Germany.
Danielczyk A; Glycotope GmbH, Robert-Roessle-Str.10, 13125 Berlin, Germany.
Goletz C; Glycotope GmbH, Robert-Roessle-Str.10, 13125 Berlin, Germany.
Lischke T; Glycotope GmbH, Robert-Roessle-Str.10, 13125 Berlin, Germany.
Flechner A; Glycotope GmbH, Robert-Roessle-Str.10, 13125 Berlin, Germany.
Dix L; Glycotope GmbH, Robert-Roessle-Str.10, 13125 Berlin, Germany.
Günzl A; Karyon Biopharma Consulting e.U., Brunn am Gebirge, Austria.
Kehler P; Glycotope GmbH, Robert-Roessle-Str.10, 13125 Berlin, Germany.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 24; Vol. 25 (3). Date of Electronic Publication: 2024 Jan 24.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/metabolism
Interleukin-15*/metabolism
Antineoplastic Agents, Immunological*/chemistry
Antineoplastic Agents, Immunological*/pharmacology
Animals ; Female ; Humans ; Mice ; Antibodies, Monoclonal/metabolism ; Disease Models, Animal ; Mucin-1/metabolism ; Tissue Distribution ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Profound postinduction hypotension precipitated by immune checkpoint inhibitors: a case report.
Autorzy:
Che L; Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, 100730, China.
Zhu A; Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, 100730, China.
Chen W; Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, 100730, China.
Yu C; Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, 100730, China. .
Pokaż więcej
Źródło:
Journal of medical case reports [J Med Case Rep] 2024 Mar 09; Vol. 18 (1), pp. 146. Date of Electronic Publication: 2024 Mar 09.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Antineoplastic Agents, Immunological*/adverse effects
Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/surgery
Hypothyroidism*/chemically induced
Female ; Humans ; Aged ; Nivolumab/adverse effects ; Immune Checkpoint Inhibitors/adverse effects ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Sarcoid-like reaction and hypothyroidism induced by PD-1 inhibitor treatment in metastatic renal cell carcinoma: a case report and literature review.
Autorzy:
Shrateh ON; Faculty of Medicine, Al-Quds University, Jerusalem, Palestine. .
Abugharbieh Y; Deparment of Radiology, Al-Ahli Hospital, Hebron, Palestine.
Asbeh YA; Department of Thoracic Surgery, Al-Ahli Hospital, Hebron, Palestine.
Hour H; Department of Oncology, Al-Ahli Hospital, Hebron, Palestine.
Awad I; Deparment of Radiology, Al-Ahli Hospital, Hebron, Palestine.
Bannoura S; Department of Pathology, Al-Ahli Hospital, Hebron, Palestine.
Pokaż więcej
Źródło:
BMC pulmonary medicine [BMC Pulm Med] 2024 Mar 08; Vol. 24 (1), pp. 123. Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:
Review; Case Reports; Journal Article
MeSH Terms:
Carcinoma, Renal Cell*/drug therapy
Carcinoma, Renal Cell*/chemically induced
Antineoplastic Agents, Immunological*/adverse effects
Kidney Neoplasms*/drug therapy
Sarcoidosis*
Humans ; Aged ; Immune Checkpoint Inhibitors/adverse effects ; Neoplasm Recurrence, Local
Czasopismo naukowe
Tytuł:
Comparisons of Non-Oral Immune-Related Adverse Events Among Patients With Cancer With Different Oral Toxicity Profiles.
Autorzy:
Xu Y; Department of Diagnostic Sciences, Tufts University School of Dental Medicine, Boston, MA, USA.; Department of Oral Medicine, Infection, and Immunity, Havard School of Dental Medicine, Boston, MA, USA.; Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, MA, USA.
Wen N; Department of Oral Medicine, Infection, and Immunity, Havard School of Dental Medicine, Boston, MA, USA.
Haddad RI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sonis ST; Department of Oral Medicine, Infection, and Immunity, Havard School of Dental Medicine, Boston, MA, USA.; Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, MA, USA.
Villa A; Oral Medicine and Oral Oncology, Miami Cancer Institute, Miami, FL, USA.; Department of Orofacial Sciences, University of California San Francisco, San Francisco, CA, USA.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2024 Mar 04; Vol. 29 (3), pp. e382-e391.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents, Immunological*/therapeutic use
Melanoma*/drug therapy
Lung Neoplasms*/drug therapy
Female ; Humans ; Middle Aged ; Aged ; Male ; Nivolumab/therapeutic use ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Is the "P-value" Alone a Sufficient Metric for the Magnitude of Clinical Benefit and Which Clinical Trial Is Actually Positive, KEYNOTE-394 or KEYNOTE-240?
Autorzy:
Kus T; Department of Medical Oncology, School of Medicine, Gaziantep University, Gaziantep, Turkey.
Aktas G; Gaziantep Medical Park Private Hospital, Gaziantep, Turkey.
Cicin I; Department of Medical Oncology, School of Medicine, Trakya University, Edirne, Turkey.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2024 Mar 04; Vol. 29 (3), pp. 190-191.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents, Immunological*/therapeutic use
Humans ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols
Czasopismo naukowe
Tytuł:
Comparative analysis of immunotherapy responses in small cell lung cancer patients with dermatomyositis.
Autorzy:
Kim SY; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.
Kim DK; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.
Choi SY; Department of pathology, College of Medicine, Chungnam National University, Daejeon, South Korea.
Chung C; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Mar; Vol. 15 (8), pp. 672-677. Date of Electronic Publication: 2024 Feb 14.
Typ publikacji:
Case Reports
MeSH Terms:
Lung Neoplasms*/complications
Lung Neoplasms*/drug therapy
Small Cell Lung Carcinoma*/complications
Small Cell Lung Carcinoma*/drug therapy
Dermatomyositis*/complications
Dermatomyositis*/drug therapy
Antineoplastic Agents, Immunological*/adverse effects
Autoimmune Diseases*/drug therapy
Humans ; Retrospective Studies ; Immunotherapy/adverse effects
Raport
Tytuł:
A Multicentric, Retrospective, Real-world Study on Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancers Treated with Pembrolizumab Monotherapy.
Autorzy:
Lerner A; North Middlesex University Hospital, London, UK.
Lee AJX; UCL Cancer Institute, University College London, London, UK; University College London Hospitals NHS Foundation Trust, London, UK.
Yan H; University College London Hospitals NHS Foundation Trust, London, UK.
Van Griethuysen J; St Bartholomew's Hospital, London, UK.
Bartlett AD; St Bartholomew's Hospital, London, UK.
Veli M; University College London Hospitals NHS Foundation Trust, London, UK; Princess Alexandra Hospital, Harlow, UK.
Jiang Y; University College London Hospitals NHS Foundation Trust, London, UK.
Luong M; University College London Hospitals NHS Foundation Trust, London, UK.
Naban N; North Middlesex University Hospital, London, UK.
Kane C; Mount Vernon Cancer Centre, Northwood, UK.
Conibear J; St Bartholomew's Hospital, London, UK.
Papadatos-Pastos D; University College London Hospitals NHS Foundation Trust, London, UK; Princess Alexandra Hospital, Harlow, UK.
Ahmad T; University College London Hospitals NHS Foundation Trust, London, UK.
Chao D; Royal Free London Hospital, London, UK.
Anand G; North Middlesex University Hospital, London, UK.
Asghar US; The Royal Marsden NHS Foundation Trust, Sutton, UK; Concr LTD, Cambridge, UK; Croydon University Hospital, Thornton Heath, UK. Electronic address: .
Pokaż więcej
Źródło:
Clinical oncology (Royal College of Radiologists (Great Britain)) [Clin Oncol (R Coll Radiol)] 2024 Mar; Vol. 36 (3), pp. 193-199. Date of Electronic Publication: 2024 Jan 16.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/pathology
Antineoplastic Agents, Immunological*/adverse effects
Antibodies, Monoclonal, Humanized*
Female ; Humans ; Retrospective Studies ; Nivolumab/adverse effects
Czasopismo naukowe
Tytuł:
Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: a case report and review of the literature.
Autorzy:
Saad R; Department of Pharmacy, American University of Beirut Medical Center, Riad El-Solh, P.O. Box 11-0236, Beirut, 1107 2020, Lebanon.
Ghaddar A; Department of Pharmacy, American University of Beirut Medical Center, Riad El-Solh, P.O. Box 11-0236, Beirut, 1107 2020, Lebanon.
Zeenny RM; Department of Pharmacy, American University of Beirut Medical Center, Riad El-Solh, P.O. Box 11-0236, Beirut, 1107 2020, Lebanon. rony_.; INSPECT-LB (Institut National de Santé Publique, d'Épidémiologie Clinique et de Toxicologie-Liban), Beirut, Lebanon. rony_.
Pokaż więcej
Źródło:
Journal of medical case reports [J Med Case Rep] 2024 Feb 22; Vol. 18 (1), pp. 107. Date of Electronic Publication: 2024 Feb 22.
Typ publikacji:
Review; Case Reports; Journal Article
MeSH Terms:
Myocarditis*/chemically induced
Urinary Bladder Neoplasms*/drug therapy
Carcinoma, Transitional Cell*
Atrioventricular Block*/chemically induced
Atrioventricular Block*/complications
Atrioventricular Block*/drug therapy
Antineoplastic Agents, Immunological*/adverse effects
Myositis*/chemically induced
Myositis*/drug therapy
Antibodies, Monoclonal, Humanized*
Humans ; Female ; Aged, 80 and over ; Creatine Kinase
Czasopismo naukowe
Tytuł:
Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors.
Autorzy:
Krizova L; Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University, U Nemocnice 499/2, 128 00, Prague 2, Czech Republic.
Benesova I; Department of Immunology, Second Faculty of Medicine, Charles University in Prague and University Hospital in Motol, Prague, Czech Republic.
Zemanova P; Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University, U Nemocnice 499/2, 128 00, Prague 2, Czech Republic.
Spacek J; Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University, U Nemocnice 499/2, 128 00, Prague 2, Czech Republic.
Strizova Z; Department of Immunology, Second Faculty of Medicine, Charles University in Prague and University Hospital in Motol, Prague, Czech Republic.
Humlova Z; Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Mikulova V; Institute of Medical Biochemistry and Laboratory Diagnostics, Laboratory of Clinical Immunology and Allergology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.
Petruzelka L; Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University, U Nemocnice 499/2, 128 00, Prague 2, Czech Republic.
Vocka M; Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University, U Nemocnice 499/2, 128 00, Prague 2, Czech Republic. .
Pokaż więcej
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Feb 21; Vol. 150 (2), pp. 99. Date of Electronic Publication: 2024 Feb 21.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Lung Neoplasms*
Antineoplastic Agents, Immunological*/therapeutic use
Carcinoma, Non-Small-Cell Lung*
Humans ; Nivolumab/therapeutic use ; Immune Checkpoint Inhibitors/therapeutic use ; Immunophenotyping ; Prospective Studies ; Biomarkers ; Hemoglobins/therapeutic use ; B7-H1 Antigen
Czasopismo naukowe
Tytuł:
Comparison of immune checkpoint inhibitors related to pulmonary adverse events: a retrospective analysis of clinical studies and network meta-analysis.
Autorzy:
Hong B; Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.; Department of Pharmacy, The Second Hospital of Sanming City, Sanming, China.; The School of Pharmacy, Fujian Medical University, Fuzhou, China.
Du B; Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, China.
Chen R; Department of Anesthesiology, The Second Hospital of Sanming City, Sanming, China.
Zheng C; Fuqing City Hospital Affiliated to Fujian Medical University, Fuzhou, China.; The School of Pharmacy, Fujian Medical University, Fuzhou, China.
Ni R; Department of Pharmacy, The First Hospital of Nanping City, Nanping, China.; The School of Pharmacy, Fujian Medical University, Fuzhou, China.
Liu M; Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China. .; The School of Pharmacy, Fujian Medical University, Fuzhou, China. .
Yang J; Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China. .; The School of Pharmacy, Fujian Medical University, Fuzhou, China. .
Pokaż więcej
Źródło:
BMC medicine [BMC Med] 2024 Feb 19; Vol. 22 (1), pp. 75. Date of Electronic Publication: 2024 Feb 19.
Typ publikacji:
Meta-Analysis; Journal Article
MeSH Terms:
Antineoplastic Agents, Immunological*/adverse effects
Neoplasms*/epidemiology
Humans ; Immune Checkpoint Inhibitors/adverse effects ; Incidence ; Network Meta-Analysis ; Clinical Trials as Topic
Czasopismo naukowe
Tytuł:
Achilles' Heel of currently approved immune checkpoint inhibitors: immune related adverse events.
Autorzy:
Yan T; Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Yu L; Department of Positron Emission Tomography-Computed Tomography (PET-CT) Center, Chenzhou No. 1 People's Hospital, Chenzhou, China.
Zhang J; Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.; School of Pharmacy, University of South China, Hengyang, China.
Chen Y; Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Fu Y; Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Tang J; Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Liao D; Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2024 Feb 12; Vol. 15, pp. 1292122. Date of Electronic Publication: 2024 Feb 12 (Print Publication: 2024).
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents, Immunological*/adverse effects
Neoplasms*
Drug-Related Side Effects and Adverse Reactions*/etiology
Drug-Related Side Effects and Adverse Reactions*/drug therapy
Humans ; Immune Checkpoint Inhibitors/adverse effects ; Antibodies, Monoclonal/adverse effects
Czasopismo naukowe
Tytuł:
Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature.
Autorzy:
Saiki R; Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. .
Katayama K; Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Saiki H; Department of Pulmonary and Critical Care Medicine, Faculty and Graduate School of Medicine, Mie University, Tsu, Japan.
Fukumori A; Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Tsujimoto K; Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Yamawaki M; Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Tanaka F; Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Takahashi D; Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Oda K; Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Suzuki Y; Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Murata T; Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Dohi K; Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Pokaż więcej
Źródło:
BMC nephrology [BMC Nephrol] 2024 Feb 09; Vol. 25 (1), pp. 51. Date of Electronic Publication: 2024 Feb 09.
Typ publikacji:
Review; Case Reports; Journal Article
MeSH Terms:
Nephrotic Syndrome*/chemically induced
Nephrotic Syndrome*/drug therapy
Antineoplastic Agents, Immunological*/adverse effects
Acute Kidney Injury*/chemically induced
Acute Kidney Injury*/therapy
Acute Kidney Injury*/complications
Nephritis, Interstitial*/chemically induced
Nephritis, Interstitial*/complications
Male ; Humans ; Aged ; Nivolumab/adverse effects ; Ipilimumab/adverse effects ; Immune Checkpoint Inhibitors/adverse effects
SCR Disease Name:
Acute Tubulointerstitial Nephritis
Czasopismo naukowe
Tytuł:
Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer.
Autorzy:
Chinchilla-Tábora LM; Department of Pathology, Institute for Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, University of Salamanca, 37007 Salamanca, Spain.
Montero JC; Department of Pathology, Institute for Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, University of Salamanca, 37007 Salamanca, Spain.; Biomedical Research Networking Centers-Oncology (CIBERONC), 28029 Madrid, Spain.
Corchete LA; Department of Medicine, Harvard Medical School, Boston, MA 02214, USA.
González-Morais I; Department of Pathology, Institute for Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, University of Salamanca, 37007 Salamanca, Spain.
Del Barco Morillo E; Department of Medical Oncology, Institute for Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, University of Salamanca, 37007 Salamanca, Spain.
Olivares-Hernández A; Department of Medical Oncology, Institute for Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, University of Salamanca, 37007 Salamanca, Spain.
Rodríguez González M; Department of Pathology, Institute for Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, University of Salamanca, 37007 Salamanca, Spain.
Sayagués JM; Department of Pathology, Institute for Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, University of Salamanca, 37007 Salamanca, Spain.; Biomedical Research Networking Centers-Oncology (CIBERONC), 28029 Madrid, Spain.
Ludeña MD; Department of Pathology, Institute for Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, University of Salamanca, 37007 Salamanca, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 08; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 08.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Antineoplastic Agents, Immunological*/therapeutic use
Carcinoma, Squamous Cell*/pathology
Head and Neck Neoplasms*/drug therapy
Humans ; Nivolumab ; Prospective Studies ; Immunotherapy ; Biomarkers ; B7-H1 Antigen
Czasopismo naukowe
Tytuł:
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
Autorzy:
Jo W; Department of Biomedical Engineering, Johns Hopkins University, Whiting School of Engineering, Baltimore, MD, United States.
Won T; Department of Pathobiology, University of Illinois Urbana-Champaign, College of Veterinary Medicine, Urbana, IL, United States.
Daoud A; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, United States.
Čiháková D; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, United States.; Department of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD, United States.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2024 Feb 05; Vol. 15, pp. 1340373. Date of Electronic Publication: 2024 Feb 05 (Print Publication: 2024).
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents, Immunological*/adverse effects
Myocarditis*/etiology
Neoplasms*/therapy
Cardiovascular System*/metabolism
Atherosclerosis*/etiology
Humans ; CTLA-4 Antigen ; Immune Checkpoint Inhibitors/adverse effects ; B7-H1 Antigen/metabolism ; Hepatitis A Virus Cellular Receptor 2 ; Programmed Cell Death 1 Receptor/metabolism ; Immunotherapy/adverse effects ; Antibodies, Monoclonal/adverse effects ; Receptors, Immunologic/therapeutic use ; Lung/pathology
Czasopismo naukowe
Tytuł:
Treatment strategies for patients with HER2-positive gastric cancer.
Autorzy:
Wang F; Department of Medical Oncology, Department of Cancer Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100032, China.
Ba Y; Department of Medical Oncology, Department of Cancer Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100032, China.; Department of GI Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
Pokaż więcej
Źródło:
Cancer biology & medicine [Cancer Biol Med] 2024 Feb 05; Vol. 20 (12).
Typ publikacji:
Editorial
MeSH Terms:
Stomach Neoplasms*/drug therapy
Antineoplastic Agents, Immunological*/therapeutic use
Humans ; Receptor, ErbB-2
Opinia redakcyjna
Tytuł:
Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer.
Autorzy:
Xin Y; Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
Liu CG; Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
Zang D; Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
Chen J; Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2024 Feb 01; Vol. 15, pp. 1343450. Date of Electronic Publication: 2024 Feb 01 (Print Publication: 2024).
Typ publikacji:
Journal Article; Review
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Gastrointestinal Microbiome*
Antineoplastic Agents, Immunological*/therapeutic use
Humans ; B7-H1 Antigen ; Immunotherapy
Czasopismo naukowe
Tytuł:
Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.
Autorzy:
Tang JD; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr. , Tampa, FL, USA.
Mills MN; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr. , Tampa, FL, USA.
Nakashima J; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr. , Tampa, FL, USA.
Dohm AE; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr. , Tampa, FL, USA.
Khushalani NI; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Forsyth PA; Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Vogelbaum MA; Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Wuthrick EJ; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr. , Tampa, FL, USA.
Yu HM; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr. , Tampa, FL, USA.
Oliver DE; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr. , Tampa, FL, USA.
Liu JKC; Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Ahmed KA; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr. , Tampa, FL, USA. .
Pokaż więcej
Źródło:
Journal of neuro-oncology [J Neurooncol] 2024 Feb; Vol. 166 (3), pp. 431-440. Date of Electronic Publication: 2024 Feb 03.
Typ publikacji:
Journal Article
MeSH Terms:
Melanoma*/pathology
Radiosurgery*/methods
Antineoplastic Agents, Immunological*/therapeutic use
Brain Neoplasms*/drug therapy
Brain Neoplasms*/secondary
Humans ; Ipilimumab/therapeutic use ; Nivolumab/therapeutic use ; Prospective Studies ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis.
Autorzy:
Li MT; Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou City, 510080, Guangdong Province, China.
He Y; Department of Pharmacy, The First Hospital of Hunan University of Chinese Medicine, Changsha, 410007, China.
Huang SY; Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou City, 510080, Guangdong Province, China.
Hu X; Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou City, 510080, Guangdong Province, China.
Chen JS; Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou City, 510080, Guangdong Province, China. .
Pokaż więcej
Źródło:
Investigational new drugs [Invest New Drugs] 2024 Feb; Vol. 42 (1), pp. 116-126. Date of Electronic Publication: 2024 Jan 23.
Typ publikacji:
Journal Article
MeSH Terms:
Myocarditis*/chemically induced
Myocarditis*/diagnosis
Myocarditis*/therapy
Antineoplastic Agents, Immunological*/adverse effects
Humans ; Aged ; Nivolumab/adverse effects ; Retrospective Studies ; Natriuretic Peptide, Brain/adverse effects ; Immunosuppressive Agents/therapeutic use ; Adrenal Cortex Hormones/adverse effects ; Creatine Kinase
Czasopismo naukowe
Tytuł:
Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective.
Autorzy:
Orozco-Leal G; Newcastle University, Newcastle upon Tyne, UK.
Johnson EE; Newcastle University, Newcastle upon Tyne, UK.
Hosseinijebeli S; Newcastle University, Newcastle upon Tyne, UK.
Robinson T; Newcastle University, Newcastle upon Tyne, UK.
Homer T; Newcastle University, Newcastle upon Tyne, UK.
Eastaugh CH; Newcastle University, Newcastle upon Tyne, UK.
Richmond C; Clinical Effectiveness Librarian, Tyne and Wear NHS Foundation Trust, Gateshead, UK.
Tanner L; Newcastle University, Newcastle upon Tyne, UK.
Meader N; Newcastle University, Newcastle upon Tyne, UK.
Kenny R; Newcastle University, Newcastle upon Tyne, UK.
Wallace SA; Newcastle University, Newcastle upon Tyne, UK.
Rice S; Newcastle University, Newcastle upon Tyne, UK. .
Pokaż więcej
Źródło:
PharmacoEconomics [Pharmacoeconomics] 2024 Feb; Vol. 42 (2), pp. 133-136. Date of Electronic Publication: 2023 Nov 20.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Antineoplastic Agents, Immunological*/therapeutic use
Humans ; Nivolumab/therapeutic use ; Neoadjuvant Therapy ; Antineoplastic Combined Chemotherapy Protocols
Czasopismo naukowe
Tytuł:
Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study.
Autorzy:
Wan G; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Department of Dermatology, Harvard Medical School, Boston, Massachusetts.
Nguyen N; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Leung BW; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Rashdan H; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Tang K; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Roster K; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Collier MR; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Ugwu-Dike PO; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Raval NS; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Alexander NA; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Jairath R; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Phillipps J; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Amadife M; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Zhang S; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Gusev A; Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts.
Chen ST; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Reynolds KL; Division of Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
LeBoeuf NR; Department of Dermatology, Dana Farber Cancer Institute, Boston, Massachusetts.
Kwatra SG; Department of Dermatology, Johns Hopkins University, Baltimore, Maryland.
Semenov YR; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Department of Dermatology, Harvard Medical School, Boston, Massachusetts. Electronic address: .
Pokaż więcej
Źródło:
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Feb; Vol. 90 (2), pp. 418-420. Date of Electronic Publication: 2023 Oct 13.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Antineoplastic Agents, Immunological*
Skin Diseases*
Neoplasms*
Humans ; Antibodies, Monoclonal ; Cohort Studies ; Immunotherapy
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies